Lisocabtagene Maraleucel Shows Deep, Durable Responses in Patients with Relapsed or Refractory MZL After at Least Two Previous Lines of Systemic Therapy By Ogkologos - February 19, 2026 277 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the marginal zone lymphoma cohort of the TRANSCEND FL study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR How Having a Creative Outlet Helped Me Cope During Cancer November 8, 2022 Advancing Patient Care Through Focused Innovation April 16, 2018 Can Using a Microwave Cause Cancer? March 25, 2021 Durvalumab Plus Chemotherapy Improves Survival in Small Cell Lung Cancer October 31, 2019 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Nirogacestat We have a Deal: What does the new UK-EU relationship mean... Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable... What to Know About At-Home DNA Tests for Detecting Cancer Risk
